ARS Pharmaceuticals Closes Merger with Silverback Therapeutics
08 Nov 2022 //
BIOSPACE
Silverback announces the FDA’s acceptance of ARS Pharma’s NDA for neffy
21 Oct 2022 //
BUSINESSWIRE
As Silverback admits defeat, ARS troops forward to fund commercialization
27 Jul 2022 //
FIERCEPHARMA
Silverback Therapeutics and ARS Pharmaceuticals Announce Merger
21 Jul 2022 //
BUSINESSWIRE
Silverback Tx to Participate in the H.C. Wainwright 24th Annual Conference
17 May 2022 //
BUSINESSWIRE
Silverback Therapeutics Reports First Quarter 2022 Financial Results
12 May 2022 //
BUSINESSWIRE
Silverback axes lead I/O candidates, lays off more than a fourth of staff
02 Apr 2022 //
ENDPTS
Silverback Reports Fourth Quarter and Full Year 2021 Financial Results
31 Mar 2022 //
BUSINESSWIRE
Silverback Tx to Present at the 42nd Annual Cowen Healthcare Conference
24 Feb 2022 //
BUSINESSWIRE
Silverback Tx to Participate in the SVB Leerink 11th Annual Conference
03 Feb 2022 //
BUSINESSWIRE
Silverback Therapeutics Presents SBT6050-201 Trial at SITC
12 Nov 2021 //
BUSINESSWIRE
Silverback Reports Q3 2021 Financial Results and Provides Business Update
10 Nov 2021 //
BUSINESSWIRE
Silverback Presents Results from Ongoing PI/Ib Study of SBT6050 in Solid Tumors
16 Sep 2021 //
BUSINESSWIRE
Silverback Therapeutics to Present Data from PI/Ib Trial of SBT6050 at ESMO 2021
13 Sep 2021 //
BUSINESSWIRE
Silverback Therapeutics to Participate in the H.C. Wainwright Conference
07 Sep 2021 //
BUSINESSWIRE
Silverback Therapeutics Reports Second Quarter 2021 Financial Results
12 Aug 2021 //
BUSINESSWIRE
Silverback Therapeutics to Participate in the 2021 Wedbush PacGrow
04 Aug 2021 //
BUSINESSWIRE
Silverback Therapeutics Announces Clinical Supply Agreement with Regeneron
07 Jul 2021 //
BUSINESSWIRE
Silverback Therapeutics to Participate in the RAD Conference
15 Jun 2021 //
BUSINESSWIRE
Silverback Therapeutics to Present SBT6290 Preclinical Data at the AACR 2021
08 Apr 2021 //
BUSINESSWIRE
Silverback Therapeutics Announces the Appointment of Dr. Maria Koehler
15 Mar 2021 //
BUSINESSWIRE
Silverback Announces Closing of Initial Public Offering and Full Exercise
08 Dec 2020 //
BUSINESSWIRE
Silverback Therapeutics Announces Pricing of Initial Public Offering
04 Dec 2020 //
BUSINESSWIRE
News Briefing: Four biotechs announce IPO terms, setting the pace to round
30 Nov 2020 //
ENDPTS
Silverback Presents Preclinical Data for SBT8230 at AASLD The Liver Meeting
13 Nov 2020 //
BUSINESSWIRE
Silverback tees up $100M IPO to push ADCs for cancer, Hep B
12 Nov 2020 //
FIERCE BIOTECH
Silverback files to go public, potentially adding to this year`s IPO
11 Nov 2020 //
ENDPTS
Solid tumor biotech Silverback Therapeutics files for a $100 million IPO
11 Nov 2020 //
RENAISSANCECAPITAL
Silverback to Present Data on Two Programs at (SITC) 35th Anniversary
09 Nov 2020 //
BUSINESSWIRE
Silverback to Present Data on Two Programs at (SITC)
09 Nov 2020 //
BUSINESSWIRE
Silverback dishes out two promotions in C-suite
25 Sep 2020 //
ENDPTS
Silverback Therapeutics quickly pulls in $85M for `an important growth phase`
24 Sep 2020 //
ENDPTS
Silverback Therapeutics nets $85M top-up to push lead ADC through phase 1
23 Sep 2020 //
FIERCE BIOTECH
Silverback Therapeutics Initiates Phase 1 Clinical Study of SBT6050
26 Aug 2020 //
BUSINESSWIRE
Silverback Therapeutics Initiates Phase 1 Clinical Study of SBT6050
26 Aug 2020 //
BUSINESSWIRE
Silverback Therapeutics Initiates Phase 1 Clinical Study of SBT6050
25 Aug 2020 //
BUSINESSWIRE
Silverback Therapeutics to Present Preclinical Data on SBT6050 Potent
22 Jun 2020 //
BUSINESSWIRE
Silverback Therapeutics Announces Presentation of Preclinical Data at ASCO
29 May 2020 //
BUSINESSWIRE
Silverback Announces Presentation of Preclinical Data at ASCO of SBT6050
29 May 2020 //
BUSINESSWIRE
Silverback Therapeutics™ to Present Preclinical Data Lead ImmunoTAC™, SBT6050
15 May 2020 //
BUSINESSWIRE
Silverback names Synthorx vet Shawver as CEO—Chutes & Ladders
26 Apr 2020 //
FIERCE BIOTECH
Silverback names Synthorx vet Shawver as CEO—Chutes & Ladders
24 Apr 2020 //
FIERCE BIOTECH